AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: EBS
Report Date: 2026-08-06
Full Report: https://amaly.io/stock/EBS

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: Emergent BioSolutions Inc. (EBS) specializes in biopharmaceutical solutions for public health threats, including biodefense vaccines. The company fails key financial screening criteria due to excessive debt (151.32% of market cap) and liquidity ratios (33.89%), exceeding thresholds across AAOIFI, MSCI, and S&P standards. Business activities are primarily compliant in healthcare but non-compliant in biodefense segments, contributing to overall non-compliance. No inclusion in major Shariah indices confirms exclusion. Purification is required for minor interest income, with a quality rating reflecting strong income compliance but critical financial and activity concerns.

Primary Compliance Concerns:
- Debt Ratio: 151.32% (exceeds 30-33% thresholds)
- Liquidity Ratio: 33.89% (exceeds 30-33% thresholds)
- Biodefense activities (40% revenue) deemed non-compliant by strict standards

Purification Requirement: 2.33%
Index Inclusion: Not included in any major Shariah indices (S&P, MSCI, FTSE, DJIM)

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 151.3%
Liquidity Ratio: 33.9%
Interest Income Ratio: 2.3%
Purification Required: 2.33%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-11-30

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-27T00:00:00Z

---
Full interactive report: https://amaly.io/stock/EBS
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.